Flash Finance

Brooks Laboratories LimitedBROOKSCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹67.57
MCap ₹199 Cr · P/E 15.1
Brooks Laboratories Limited — Stock analysis & AI research Brooks Laboratories Limited — Seasonality — best & worst months Brooks Laboratories Limited — Technical setup — score, trend, support & resistance Brooks Laboratories Limited — Live exchange announcements
📈 Stocks Above Anchored VWAP 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹23 Cr
Sales · Jun 2026
-10.0% YoY
₹2 Cr
Operating Profit · Jun 2026
-40.4% YoY
8.1%
OPM % · Jun 2026
-34.1% YoY
₹-2 Cr
Net Profit · Jun 2026
-118.6% YoY
₹-0.61
EPS · Jun 2026
-118.8% YoY

📝 Brooks Laboratories Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Brooks Laboratories Limited reported revenue of ₹23 crore for the quarter ended June 2026 (Q1 FY27), down 10.0% from ₹26 crore in the same quarter last year, and up 13.6% sequentially over the March 2026 quarter.

The company reported a net loss of ₹2 crore, against a net profit of ₹10 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-0.61.

Operating profit stood at ₹2 crore — an operating margin (OPM) of 8.1%, compared with 12.3% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Brooks Laboratories Limited posted revenue of ₹86 crore, a decline of 14.7% over FY25, with a net profit of ₹25 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹83 crore with a net profit of ₹13 crore.

Valuation snapshot

At the current price of ₹67.57, BROOKS has a market capitalisation of ₹199 crore and a trailing P/E of about 15.1.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 25th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 52.62%, foreign institutional investors (FIIs) 0.17%, domestic institutional investors (DIIs) 10.38%, public shareholders 36.84% of Brooks Laboratories Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹199 Cr
Current Price ?
₹67.6
P/E ?
15.07below ind
Industry P/E ?
37.20
P/B ?
1.63
P/S ?
2.39
P/FCF ?
33.17
Enterprise Value ?
₹208 Cr
EV/EBITDA ?
35.88
PEG ?
0.32
Earnings Yield ?
2.0%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹83 Cr
OPM ?
7.0%
Profit after tax (TTM) ?
₹13 Cr
EPS (TTM) ?
₹4.48
ROCE ?
21.0%
ROE ?
10.8%
ROA ?
8.9%
Growth
Sales — latest qtr ?
₹23 Cr
PAT — latest qtr ?
₹-2 Cr
YoY qtr sales growth ?
-10.0%
YoY qtr profit growth ?
-118.6%
Sales growth (3y) ?
11%
Sales growth (5y) ?
2%
Profit growth (3y) ?
47%
Profit growth (5y) ?
27%
Financial Health
Debt ?
₹9 Cr
Debt to Equity ?
0.07
Interest Coverage ?
6.5
Current Ratio ?
N/A
Ownership
Promoter holding ?
52.62%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
-2.7%
Return 6 months ?
-0.0%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 151316242218182138232623172023 -10.0% +13.6%
Operating Profit -9-402100-32233112 -40.4% +173.9%
Other Income 0000-41-20-5106510 -18.6% -86.9%
Interest 100000000000000 -31.8% +128.3%
Depreciation 200000001000000 +6.0% +1.3%
Profit Before Tax -11-4-4-2-4-10-2-4-5-110852-2 -118.6% -216.8%
Net Profit -9-4-4-2-4-10-2-4-5-110852-2 -118.6% -217.6%
EPS -2.03-1.64-1.81-0.64-1.51-3.77-0.94-1.51-1.75-0.543.252.711.870.52-0.61 -118.8% -217.3%
OPM % -55.9% -29.3% 0.2% 7.1% 5.0% 2.1% 1.6% -16.4% 4.8% 6.6% 12.3% 10.8% 4.4% 3.4% 8.1% -34.1% +138.2%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹100 Cr ₹86 Cr ₹83 Cr -14.7%
Operating Profit ₹0 Cr ₹7 Cr ₹6 Cr +2537.0%
OPM % 0.27% 8.24% 6.97% +2951.9%
NPM % -12.34% 28.67% 15.88% +332.3%
Other Income ₹-6 Cr ₹13 Cr ₹13 Cr +300.8%
Depreciation ₹2 Cr ₹2 Cr ₹2 Cr -20.7%
Interest ₹1 Cr ₹1 Cr ₹1 Cr -29.6%
EBIT ₹-2 Cr ₹5 Cr ₹4 Cr +415.6%
PBT ₹-12 Cr ₹25 Cr ₹13 Cr +301.5%
Tax ₹0 Cr — — —
Net Profit ₹-12 Cr ₹25 Cr ₹13 Cr +298.2%
EPS ₹-4.74 ₹8.35 ₹4.49 +276.2%
Material Cost ₹54 Cr ₹40 Cr ₹38 Cr -26.5%
Employee Cost ₹13 Cr ₹11 Cr ₹12 Cr -11.8%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 25262929 +0.0%
Reserves 49396993 +34.8%
Borrowings 7689 +12.5%
Other Liabilities 29191817 -5.6%
Total Liabilities 11090124148 +19.4%
Fixed Assets 15141415 +7.1%
CWIP 0001 —
Investments 64437492 +24.3%
Other Assets 31343640 +11.1%
Total Assets 11090124148 +19.4%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -14-1039 +200.0%
Cash from Investing Activity 00-45-3 +93.3%
Cash from Financing Activity 1110420 -100.0%
Net Cash Flow -30-07 —
Free Cash Flow -15-1026 +200.0%
CFO/OP 48%56%-26%132% +607.7%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 74758869 -21.6%
Inventory Days 80606179 +29.5%
Days Payable 165979082 -8.9%
Cash Conversion Cycle -12385966 +11.9%
Working Capital Days -37344334 -20.9%
ROCE % -30%-25%-10%21% +310.0%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 52.62%52.62%52.62%52.62% +0.0%
FIIs 0.00%0.01%0.09%0.17% +88.9%
DIIs 10.38%10.38%10.38%10.38% +0.0%
Public 37.00%37.00%36.91%36.84% -0.2%
No. of Shareholders 10,31710,07810,53210,741 +2.0%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 BROOKS Brooks Laboratories ₹61.02 180 13.6 83 13 7.0% 15.9% -14.7% 298.2% -10.0% -118.6%
❓ Frequently asked questions
What was Brooks Laboratories Limited's revenue in Q1 FY27?
Brooks Laboratories Limited reported revenue of ₹23 crore for the quarter ended June 2026 (Q1 FY27), down 10.0% from ₹26 crore in the same quarter last year, and up 13.6% sequentially over the March 2026 quarter.
What was Brooks Laboratories Limited's net profit in Q1 FY27?
The company reported a net loss of ₹2 crore, against a net profit of ₹10 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-0.61.
What is BROOKS's market capitalisation and P/E ratio?
At the current price of ₹67.57, BROOKS has a market capitalisation of ₹199 crore and a trailing P/E of about 15.1.
Who owns Brooks Laboratories Limited? (shareholding pattern)
As of Mar 2026, promoters held 52.62%, foreign institutional investors (FIIs) 0.17%, domestic institutional investors (DIIs) 10.38%, public shareholders 36.84% of Brooks Laboratories Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI